Aprepitant to Mitigate Opioids' Cognitive Side Effects

Trial Profile

Aprepitant to Mitigate Opioids' Cognitive Side Effects

Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Aprepitant (Primary) ; Aprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms CognAp
  • Most Recent Events

    • 01 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 30 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top